Back to Browse Journals » Vascular Health and Risk Management » Volume 6

New standards in hypertension and cardiovascular risk management: focus on telmisartan

Authors Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Published 4 March 2010 Volume 2010:6 Pages 113—133

DOI https://doi.org/10.2147/VHRM.S7857

Review by Single-blind

Peer reviewer comments 4

Domenico Galzerano1, Cristina Capogrosso4, Sara Di Michele2, Antonio Galzerano1, Paola Paparello1, Diana Lama3, Carlo Gaudio2

1Department of Cardiology, San Gennaro Hospital, Naples, Italy; 2Department of Heart and Great Vessels, A. Reale, La Sapienza University, Rome, Italy; 3V Division of Internal Medicine, II University, Naples, Italy; 4Cardiology Division, San Giovanni Bosco Hospital, Naples, Italy

Abstract: Blockade of the renin–angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua. Telmisartan is an angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure. In patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensive agents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval. There is also clinical evidence that telmisartan reduces left ventricular hypertrophy, reduces arterial stiffness and the recurrence of atrial fibrillation, and confers renoprotection. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) study has demonstrated that telmisartan has similar cardiovascular protective effects to ramipril in a large, high-risk patient population but was better tolerated. The powerful and sustained blood pressure control apparent in clinical trials, together with cardiovascular protection and tolerability demonstrated in ONTARGET® means that telmisartan may be a preferred option for patients with hypertension.

Keywords: angiotensin II receptor blocker, cardiovascular disease, hypertension, renin–angiotensin system, telmisartan

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection

Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Vascular Health and Risk Management 2010, 6:479-494

Published Date: 22 June 2010

Readers of this article also read:

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

ElHalawani H, Abdel-Rahman O

Therapeutics and Clinical Risk Management 2015, 11:1123-1132

Published Date: 28 July 2015

Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients

Daud ZAM, Tubie B, Sheyman M, Osia R, Adams J, Tubie S, Khosla P

Vascular Health and Risk Management 2013, 9:747-761

Published Date: 28 November 2013

Critical review of cancer risk associated with angiotensin receptor blocker therapy

Wuerzner G, Burnier M, Waeber B

Vascular Health and Risk Management 2011, 7:741-747

Published Date: 12 December 2011

Cancer patient-centered home care: a new model for health care in oncology

Tralongo P, Ferraù F, Borsellino N, Verderame F, Caruso M, Giuffrida D, Butera A, Gebbia V

Therapeutics and Clinical Risk Management 2011, 7:387-392

Published Date: 9 September 2011

Pegylated liposomal doxorubicin in the management of ovarian cancer

Gabriella Ferrandina, Giacomo Corrado, Angelo Licameli, et al

Therapeutics and Clinical Risk Management 2010, 6:463-483

Published Date: 29 September 2010

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

Kanako Bokuda, Atsuhiro Ichihara, Mariyo Sakoda, et al

Vascular Health and Risk Management 2010, 6:571-578

Published Date: 5 July 2010

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection

Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Vascular Health and Risk Management 2010, 6:479-494

Published Date: 22 June 2010

Influence of demographic and metabolic variables on forearm blood flow and vascular conductance in individuals without overt heart disease

Thiago E Sartori, Rafael AB Nunes, Gisela T da Silva, et al

Vascular Health and Risk Management 2010, 6:431-437

Published Date: 31 May 2010

Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine

David Feldman, Terry S Elton, Doron M Menachemi, et al

Vascular Health and Risk Management 2010, 6:387-397

Published Date: 24 May 2010

Isolated spontaneous dissection of the celiac trunk in a patient with bicuspid aortic valve

Abdel-Rauf Zeina, Alicia Nachtigal, Anton Troitsa, et al

Vascular Health and Risk Management 2010, 6:383-386

Published Date: 19 May 2010